

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Previously Presented) A method to enhance the cytotoxicity of an antineoplastic drug for the treatment of a disorder of abnormal cell proliferation, the method comprising administering an effective amount of the antineoplastic drug to a host in need of such treatment in combination with an effective cytotoxicity-increasing amount of an antioxidant, wherein the antioxidant is a mono-ester or di-ester of probucol.

2-18. (Cancelled)

19. (Previously Presented) The method according to claim 1 wherein the mono-ester or di-ester of probucol is an ester of succinic acid, glutaric acid, adipic acid, suberic acid, sebamic acid, azelaic acid or maleic acid.

20-22. (Cancelled)

23. (Previously Presented) The method of claim 1, wherein the antineoplastic agent is selected from the group consisting of Aceglatone; Aclarubicin; Altretamine; Aminoglutethimide; 5-Aminolevulinic Acid; Amsacrine; Anastrozole; Ancitabine Hydrochloride; 17-1A Antibody; Antilymphocyte Immunoglobulins; Antineoplaston A10; Asparaginase; Pegaspargase; Azacitidine; Azathioprine; Batimastat; Benzoporphyrin Derivative; Bicalutamide; Bisantrene Hydrochloride; Bleomycin Sulphate; Brequinar Sodium; Broxuridine; Busulphan; Campath-IH; Caracemide; Carbetimer; Carboplatin; Carboquone; Carmofur; Carmustine; Chlorambucil; Chlorozotocin; Chromomycin; Cisplatin; Cladribine; Corynebacterium parvum; Cyclophosphamide; Cyclosporin; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Diaziquone; Dichlorodiethylsulphide; Didemnin B.; Docetaxel; Doxifluridine; Doxorubicin Hycloride; Droxofifene; Echinomycin; Edatrexate; Elliptinium; Elmustine; Enloplatin; Enocitabine; Epirubicin Hydrochloride; Estramustine Sodium Phosphate;

Etanidazole; Ethoglucid; Etoposide; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flutamide; Formestane; Fotemustine; Gallium Nitrate; Gencitabine; Gusperimus; Homoharringtonine; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine; Imrosulfan Tosylate; Inolimomab; Interleukin-2; Irinotecan; JM-216; Letrozole; Lithium Gamolenate; Lobaplatin; Lomustine; Lonidamine; Mafosfamide; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Miboplatin; Miltefosine; Misonidazole; Mitobronitol; Mitoguazone Dihydrochloride; Mitolactol; Mitomycin; Mitotane; Mitozantrone Hydrochloride; Mizoribine; Mopidamol; Multialchipeptide; Muromonab-CD3; Mustine Hydrochloride; Mycophenolic Acid; Mycophenolate Mofetil; Nedaplatin; Nilutamide; Nimustine Hydrochloride; Oxaliplatin; Paclitaxel; PCNU; Penostatin; Peplomycin Sulphate; Pipobroman; Pirarubicin; Piritrexim Isethionate; Piroxantrone Hydrochloride; Plicamycin; porfimer Sodium; Prednimustine; Procarbazine Hydrochloride; Raltitrexed; Ranimustine; Razoxane; Rogletimide; Roquinimex; Sebriplatin; Semustine; Sirolimus; Sizofiran; Sobuzoxane; Sodium Bromebrate; Sparfusic Acid; Sparfosate Sodium; Sreptozocin; Sulofenur; Tacrolimus; Tamoxifen; Tegafur; Teloxantrone Hydrochloride; Temozolomide; Teniposide; Testolactone; Tetrasodium Mesotetraphenylporphine-sulphonate; Thioguanine; Thioinosine; Thiotepa; Topotecan; Toremifene; Treosulfan; Trimetrexate; Trofosfamide; Tumor Necrosis Factor; Ubenimex; Uramustine; Vinblastine Sulphate; Vincristine Sulphate; Vindesine Sulphate; Vinorelbine Tartrate; Vorozole; Zinostatin; Zolimomab Aritox; and Zorubicin Hydrochloride.

24. (Cancelled)

25. (Cancelled)

26. (Previously Presented) The method of claim 1, wherein the abnormal cell proliferation is a hyperproliferative or preneoplastic lesion.

27-30. (Cancelled)

31. (Previously Presented) The method according to claim 1, wherein the antineoplastic drug is carboplatin.

32. (Previously Presented) The method according to claim 1, wherein the antineoplastic drug is cisplatin.
33. (Previously Presented) The method according to claim 1, wherein the antineoplastic drug is doxorubicin.
34. (Previously Presented) The method according to claim 1, wherein the antineoplastic drug is daunorubicin.
35. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-succinic acid ester.
36. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-glutaric acid ester.
37. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-adipic acid ester.
38. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-suberic acid ester.
39. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-azelaic acid ester.
40. (Previously Presented) The method according to claim 1, wherein the mono- or di-ester of probucol is the mono-maleic acid ester.